Roivant Sciences secures rights to develop Ligand’s glucagon receptor antagonist

This article was originally published here

Ligand Pharmaceuticals has signed a license agreement granting Roivant Sciences exclusive global rights to develop and commercialize its LGD-6972 glucagon receptor antagonist (GRA).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply